The drug development landscape in Asia Pacific is accelerating more than ever before. Emerging biotech companies now face multiple hurdles in the clinical development process – from learning to prioritize the right target indication, effectively designing robust clinical study program with integration of right biomarkers ultimately seeking compressed development timelines.

With increasing trial complexity and decreasing success rate for oncology assets in the clinical productivity index, it is critical for small sponsors to identify the right target disease indication and consider the appropriate biomarker strategies right from the start of your early clinical development plan.

• Learn how Indication Prioritization analysis can increase the return of investment of your oncology assets
• Gain insights into how IQVIA Biotech can support your oncology early assets through our CDP oncology program
• Learn how to integrate biomarker strategies in the framework of clinical trial and laboratory operations

Join this webinar to learn how JAPAC IQVIA Biotech leverages data and expertise to support your strategic drug development for early oncology assets to ensure your success.

Key speakers

Christopher Hart
Senior Director, Drug Development Lead, Planning and Design Operations

Eric Groves
Vice President, Strategic Drug Development, Design and Delivery Innovation

Bradley Smith
Vice President, Strategic Drug Development, Translational Medicine

Megan McCausland
Scientific Advisor, Q2 Solutions